met required recruitment anti-tumoural neutrophils 
mutations amplification met proto-oncogene involved pathogenesis several tumours- rely constitutive engagement pathway growth survival however met expressed cancer cells also tumour-associated stromal cells although precise role compartment well characterized- show met required neutrophil chemoattraction cytotoxicity response ligand hepatocyte growth factor hgf met deletion mouse neutrophils enhances tumour growth metastasis phenotype correlates reduced neutrophil infiltration primary tumour metastatic sites similarly met necessary neutrophil transudation colitis skin rash peritonitis mechanistically met induced tumour-derived tumour necrosis factor tnf-alpha inflammatory stimuli mouse human neutrophils induction instrumental neutrophil transmigration across activated endothelium inducible nitric oxide synthase production upon hgf stimulation consequently hgf/met-dependent nitric oxide release neutrophils promotes cancer cell killing abates tumour growth metastasis systemic administration met kinase inhibitor prove therapeutic benefit met targeting cancer cells partly countered pro-tumoural effect arising met blockade neutrophils work identifies unprecedented role met neutrophils suggests potential achilles heel met-targeted therapies cancer supports rationale evaluating anti-met drugs certain inflammatory diseases 
